Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1392P - Submucosal versus subserosal approaches toward optimized indocyanine green tracer-guided lymphadenectomy for gastric cancer: A randomized clinical trial

Date

16 Sep 2021

Session

ePoster Display

Topics

Tumour Site

Gastric Cancer

Presenters

Qi-Yue Chen

Citation

Annals of Oncology (2021) 32 (suppl_5): S1040-S1075. 10.1016/annonc/annonc708

Authors

Q. Chen1, L. Zhuang2, Q. Zhong3, C. Huang1

Author affiliations

  • 1 Department Of Gastric Surgery, Fujian Medical University Union Hospital, 350000 - Fuzhou/CN
  • 2 Department Of Neurology, Fujian Medical University Union Hospital, 350000 - Fuzhou/CN
  • 3 Department Of Gastric Surgery, Fujian Medical University Union Hospital, 350001 - Fuzhou/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1392P

Background

Application of indocyanine green (ICG) fluorescence imaging is effective in guiding laparoscopic radical lymphadenectomy for gastric cancer. However, the optimal approach for ICG injection is controversial. We aimed to compare the efficacy and cost-effectiveness of ICG injection between the preoperative submucosal and intraoperative subserosal approaches for lymph node (LN) tracing during laparoscopic gastrectomy.

Methods

This phase III, open-label, randomized controlled trial was conducted at a tertiary teaching center in China. Patients aged 18–75 years who had cT1–cT4a, N0/+, M0 histologically proven gastric adenocarcinoma were randomly assigned (1:1) to receive either intraoperative subserosal injection or submucosal injection of ICG 1 day before surgery and underwent ICG fluorescence imaging-guided lymphadenectomy. The primary endpoint was the total number of retrieved LNs and was analyzed according to the modified intention-to-treat principle. The study is registered with ClinicalTrials.gov, number NCT04219332.

Results

Between December 31, 2019 and October 27, 2020, 266 patients were randomized to either the submucosal group (n=133) or the subserosal group (n=133). The full analysis set consisted of 130 participants in the submucosal group and 129 in the subserosal group. The mean (SD) total number of retrieved LNs was 49.8 (14.6) and 49.2 (14.0) in the submucosal and subserosal groups, respectively, with no significant difference (P=.71). The rate of LN noncompliance in the submucosal group was comparable to that in the subserosal group (32.3% vs. 33.3%, P=.86). The mean fluorescence cost in the submucosal group was higher than that in the subserosal group ($335.3 vs. $182.4; P<.001). The overall treatment satisfaction score was lower in the submucosal group than in the subserosal group (70.5 vs. 76.1%, P=.048).

Conclusions

ICG administered by subserosal injection was comparable to that administered by submucosal injection for LN tracing in gastric cancer. However, the former approach imposed a lower economic and mental burden on patients undergoing laparoscopic D2 lymphadenectomy.

Clinical trial identification

NCT04219332.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.